A detailed history of Redmile Group, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 1,383,366 shares of VERV stock, worth $6.29 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares
1,383,366
Previous 1,463,406 5.47%
Holding current value
$6.29 Million
Previous $7.14 Million 6.25%
% of portfolio
0.44%
Previous 0.47%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.4 - $7.86 $352,176 - $629,114
-80,040 Reduced 5.47%
1,383,366 $6.7 Million
Q2 2024

Aug 14, 2024

SELL
$4.76 - $12.79 $671,678 - $1.8 Million
-141,109 Reduced 8.79%
1,463,406 $7.14 Million
Q1 2024

May 15, 2024

SELL
$10.81 - $17.96 $1.23 Million - $2.05 Million
-114,154 Reduced 6.64%
1,604,515 $21.3 Million
Q4 2023

Feb 14, 2024

BUY
$8.84 - $18.7 $5.81 Million - $12.3 Million
656,709 Added 61.84%
1,718,669 $24 Million
Q2 2023

Aug 14, 2023

SELL
$13.34 - $19.9 $783,311 - $1.17 Million
-58,719 Reduced 5.24%
1,061,960 $19.9 Million
Q1 2023

May 15, 2023

SELL
$14.3 - $24.01 $1.45 Million - $2.43 Million
-101,224 Reduced 8.28%
1,120,679 $16.2 Million
Q4 2022

Feb 14, 2023

SELL
$17.85 - $40.7 $5.06 Million - $11.5 Million
-283,223 Reduced 18.82%
1,221,903 $23.6 Million
Q3 2022

Nov 14, 2022

SELL
$15.63 - $41.49 $5.13 Million - $13.6 Million
-328,421 Reduced 17.91%
1,505,126 $51.7 Million
Q2 2022

Aug 15, 2022

SELL
$11.14 - $23.17 $19,840 - $41,265
-1,781 Reduced 0.1%
1,833,547 $28 Million
Q1 2022

May 16, 2022

BUY
$20.92 - $39.36 $2.65 Million - $4.99 Million
126,792 Added 7.42%
1,835,328 $41.9 Million
Q4 2021

Feb 14, 2022

SELL
$31.94 - $54.82 $5.13 Million - $8.8 Million
-160,494 Reduced 8.59%
1,708,536 $63 Million
Q3 2021

Nov 15, 2021

SELL
$46.0 - $73.99 $3.11 Million - $4.99 Million
-67,500 Reduced 3.49%
1,869,030 $87.8 Million
Q2 2021

Aug 16, 2021

BUY
$31.92 - $60.25 $61.8 Million - $117 Million
1,936,530 New
1,936,530 $117 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $273M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.